chemodenervation

ApprovedSmall molecule

UUniversity of California, Los Angeles

chemodenervation is one of 3 small molecule programs targeting Facial Paralysis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Facial ParalysisActive, not recruiting

Facial ParalysisApproved

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Facial Paralysis

#DrugCompanyPhaseTrials

chemodenervation

UUniversity of California, Los Angeles

Approved

1 2

Mecobalamin

Eisai

Preclinical

1 3

Botox

RRevance Therapeutics, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Botulinum Toxin1 trial

Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques

Terminated·UUniversity of California, Los Angeles·Phase 4·NCT00992108·17 enrolled

Facial Paralysis1 trial

Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT04148872·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for chemodenervation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chemodenervation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chemodenervation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, Los Angeles

chemodenervation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Botulinum Toxin1 trial

Facial Paralysis1 trial

References

Drug Info

Quick Facts

Related News